MX2015005486A - Usos de bremelanotida en terapia para la disfuncion sexual femenina. - Google Patents

Usos de bremelanotida en terapia para la disfuncion sexual femenina.

Info

Publication number
MX2015005486A
MX2015005486A MX2015005486A MX2015005486A MX2015005486A MX 2015005486 A MX2015005486 A MX 2015005486A MX 2015005486 A MX2015005486 A MX 2015005486A MX 2015005486 A MX2015005486 A MX 2015005486A MX 2015005486 A MX2015005486 A MX 2015005486A
Authority
MX
Mexico
Prior art keywords
bremelanotide
sexual dysfunction
female sexual
therapy
women
Prior art date
Application number
MX2015005486A
Other languages
English (en)
Other versions
MX362610B (es
Inventor
Carls Spana
Robert Jordan
Jeffrey D Edelson
Original Assignee
Palatin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50628268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015005486(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Palatin Technologies Inc filed Critical Palatin Technologies Inc
Publication of MX2015005486A publication Critical patent/MX2015005486A/es
Publication of MX362610B publication Critical patent/MX362610B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)

Abstract

El uso de una dosis administrada por vía subcutánea de entre aproximadamente 1.0 mg y 175 mg de bremelanotida o una sal farmacéuticamente aceptable de esta para el tratamiento de la disfunción sexual femenina en mujeres a la vez que se reducen o minimizan los efectos secundarios indeseados.
MX2015005486A 2012-11-05 2013-11-05 Usos de bremelanotida en terapia para la disfunción sexual femenina. MX362610B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722511P 2012-11-05 2012-11-05
US201361770535P 2013-02-28 2013-02-28
PCT/US2013/068386 WO2014071339A2 (en) 2012-11-05 2013-11-05 Uses of bremelanotide in therapy for female sexual dysfunction

Publications (2)

Publication Number Publication Date
MX2015005486A true MX2015005486A (es) 2015-11-13
MX362610B MX362610B (es) 2019-01-28

Family

ID=50628268

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005486A MX362610B (es) 2012-11-05 2013-11-05 Usos de bremelanotida en terapia para la disfunción sexual femenina.

Country Status (24)

Country Link
US (7) US9352013B2 (es)
EP (1) EP2916856B2 (es)
JP (1) JP6567971B2 (es)
KR (1) KR102253526B1 (es)
CN (2) CN104755094A (es)
AU (1) AU2013337341B2 (es)
BR (1) BR112015009936A8 (es)
CA (1) CA2890081A1 (es)
DK (1) DK2916856T4 (es)
EA (1) EA032959B9 (es)
ES (1) ES2701444T5 (es)
FI (1) FI2916856T4 (es)
GE (1) GEP20196947B (es)
HK (1) HK1211227A1 (es)
IL (1) IL238276B (es)
MX (1) MX362610B (es)
MY (1) MY179755A (es)
NZ (1) NZ707246A (es)
PH (1) PH12015500915A1 (es)
PL (1) PL2916856T5 (es)
SG (1) SG11201502949QA (es)
UA (1) UA118656C2 (es)
WO (1) WO2014071339A2 (es)
ZA (1) ZA201503128B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590209B2 (en) * 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
DE60112440T2 (de) * 2000-05-31 2006-04-20 Novo Nordisk A/S Wegwerfbare zweispitzige injektionsnadel
CA2453515A1 (en) 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
BRPI0518961A2 (pt) * 2004-12-09 2008-12-16 West Pharm Serv Inc acoplamento para dispositivo de injeÇço automÁtica
WO2009120656A1 (en) * 2008-03-24 2009-10-01 Palatin Technologies, Inc. Pharmaceutical for ocular indications
EA018630B1 (ru) * 2008-06-09 2013-09-30 Палатин Текнолоджиз, Инк. Специфичные к меланокортиновым рецепторам пептиды для лечения сексуальной дисфункции
WO2011060352A1 (en) * 2009-11-16 2011-05-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
CN103118737B (zh) * 2010-04-21 2015-05-20 艾伯维生物技术有限公司 用于治疗药剂的受控输送的可佩戴自动注射装置

Also Published As

Publication number Publication date
PH12015500915B1 (en) 2015-06-29
CN104755094A (zh) 2015-07-01
EP2916856A4 (en) 2016-06-22
ZA201503128B (en) 2016-11-30
US10286034B2 (en) 2019-05-14
EA201590760A1 (ru) 2015-10-30
US20240335502A1 (en) 2024-10-10
PL2916856T3 (pl) 2019-02-28
EP2916856A2 (en) 2015-09-16
ES2701444T3 (es) 2019-02-22
JP2016503406A (ja) 2016-02-04
ES2701444T5 (es) 2024-05-21
US20190216888A1 (en) 2019-07-18
WO2014071339A2 (en) 2014-05-08
FI2916856T4 (fi) 2024-01-15
MY179755A (en) 2020-11-12
SG11201502949QA (en) 2015-06-29
NZ707246A (en) 2019-03-29
IL238276A0 (en) 2015-06-30
EP2916856B2 (en) 2023-10-18
HK1211227A1 (en) 2016-05-20
US20180085425A1 (en) 2018-03-29
US20220362328A1 (en) 2022-11-17
CN117860866A (zh) 2024-04-12
IL238276B (en) 2020-04-30
GEP20196947B (en) 2019-02-11
WO2014071339A3 (en) 2014-06-12
EP2916856B1 (en) 2018-09-19
BR112015009936A8 (pt) 2019-09-17
US9352013B2 (en) 2016-05-31
US20210060120A1 (en) 2021-03-04
JP6567971B2 (ja) 2019-08-28
US20140378392A1 (en) 2014-12-25
KR102253526B1 (ko) 2021-05-18
PL2916856T5 (pl) 2024-01-29
US9700592B2 (en) 2017-07-11
DK2916856T4 (da) 2024-01-22
DK2916856T3 (en) 2019-01-14
AU2013337341B2 (en) 2018-02-22
PH12015500915A1 (en) 2015-06-29
US20150231196A1 (en) 2015-08-20
EA032959B9 (ru) 2019-11-27
CA2890081A1 (en) 2014-05-08
UA118656C2 (uk) 2019-02-25
MX362610B (es) 2019-01-28
KR20150081345A (ko) 2015-07-13
AU2013337341A1 (en) 2015-05-07
EA032959B1 (ru) 2019-08-30
BR112015009936A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
MX2018001659A (es) Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer.
NZ732507A (en) Improved compositions for treating muscular dystrophy
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
NZ714963A (en) Compositions and methods for treating anemia
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
PH12018502134A1 (en) Methods of treating pediatric cancers
MX2024010140A (es) Nuevos metodos.
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
WO2013188210A3 (en) Treatment of side effects associated with parkinson's disease treatments
MX2022000143A (es) Metodos novedosos.
MX2021014523A (es) Metodos para tratar colangiocarcinoma.
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
UA115250C2 (uk) Фармацевтичні комбінації
PH12015500915A1 (en) Bremelanotide therapy for female sexual dysfunction
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
MX349767B (es) Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil) -naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular.
NZ599227A (en) Therapeutic agent for chronic pain
MX2018001528A (es) Composicion farmaceutica que comprende sumatriptan para tratamiento de migraña.
TN2013000336A1 (en) 5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy.
ZA202102913B (en) Dosage regime

Legal Events

Date Code Title Description
FG Grant or registration